Overview

Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.

Status:
Recruiting

Trial end date:
2022-01-01

Target enrollment:

Participant gender:

Summary

The study has a phase Ib and a phase II part. - The phase Ib aims to evaluate the safety and tolerability of durvalumab in combination with a dose- dense EC regimen in a neoadjuvant setting for early breast cancer. - The phase II aims to explore the efficacy of durvalumab in combination with a dose-dense EC regimen in a neoadjuvant setting for early breast cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Grand Hôpital de Charleroi

Collaborator:

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Treatments:

Albumin-Bound Paclitaxel
Antibodies, Monoclonal
Cyclophosphamide
Durvalumab
Epirubicin
Paclitaxel
Phenobarbital